Clinical trial

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173

Study summary

ClinicalTrials.gov

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Domvanalimab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Zimberelimab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxel View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-02-08

PhasePHASE2

Conditions

Non Small Cell Lung Cancercandidate · MONDO: non-small cell lung carcinoma

Nonsquamous Non Small Cell Lung Cancerunresolved

Squamous Non Small Cell Lung Cancerunresolved

Lung Cancerverified · MONDO: lung cancer

Interventions

DomvanalimabDRUG

ZimberelimabDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxelDRUG · verified · RxNorm: paclitaxel

PemetrexedDRUG · verified · RxNorm: pemetrexed

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Arcus Biosciences, Inc.lead sponsor

Gilead Sciencescollaborator

Mapped research locations

SeoulSouth Korea1 IstanbulTurkey (Türkiye)1 TaichungTaiwan1 AnkaraTurkey (Türkiye)1 Hong KongHong Kong1 BangkokThailand1 IncheonSouth Korea1 DaeguSouth Korea1 ColumbusGeorgia, United States1 Kuala LumpurMalaysia1 PretoriaSouth Africa1 AdanaTurkey (Türkiye)1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04736173 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.